Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Crispr Therapeutics Ag
(NQ:
CRSP
)
55.24
-0.49 (-0.88%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Crispr Therapeutics Ag
< Previous
1
2
...
20
21
22
23
24
25
26
27
Next >
Vertex, Gene-Editing Leader, Heads 5 Resilient Stocks In Bear Market
October 01, 2022
Vertex flashed a buy signal on positive gene-editing news.
Via
Investor's Business Daily
Stock Market Falls, S&P 500 Hits Bear Lows; Biogen, Nike, Micron Are Key Movers: Weekly Review
September 30, 2022
The major indexes fell, with the S&P 500 breaking below bear market lows.
Via
Investor's Business Daily
MaxCyte Inks Platform License With Vertex For Gene-Editing Program For Rare Blood Disorders
September 28, 2022
MaxCyte Inc (NASDAQ: MXCT) has signed a
Via
Benzinga
What Is Going on With Grom Social (GROM) Stock Today?
September 27, 2022
Grom Social (GROM) stock is heading higher on Tuesday following news of Chelsea and Matt Giegerich signing a deal with Curiosity Ink Media.
Via
InvestorPlace
Why Are Crypto Mining Stocks RIOT, MARA, HUT Up Today?
September 27, 2022
Crypto mining stocks are on the move Tuesday as investors react to Bitcoin (BTC) breaking past the $20,000 price point today!
Via
InvestorPlace
Where CRISPR Therapeutics Stands With Analysts
August 02, 2022
CRISPR Therapeutics (NASDAQ:CRSP) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Why Is Crispr Therapeutics (CRSP) Stock Up Today?
September 27, 2022
Crispr Therapeutics (CRSP) stock is gaining on Tuesday after the FDA granted exagamglogene autotemcel (exa-cel) a rolling review.
Via
InvestorPlace
Crispr Stock Jumps After Unveiling Timeline For FDA Submission Of First-Ever CRISPR Drug
September 27, 2022
Crispr and Vertex nailed down the timeline for their blood diseases gene editor.
Via
Investor's Business Daily
Why CRISPR Therapeutics Stock Is Rising Today
September 27, 2022
CRISPR Therapeutics AG (NASDAQ: CRSP) shares are trading higher Tuesday after the company and Vertex Pharmaceuticals Inc (NASDAQ: VRTX) announced the U.S.
Via
Benzinga
S&P 500 Giant Leads 5 Stocks Showing Strength In Bear Market
September 24, 2022
Eli Lilly leads medical stocks setting up and showing relative strength.
Via
Investor's Business Daily
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $3,700 Today
September 20, 2022
CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 20.85% on an annualized basis producing an average annual return of 29.91%. Currently, CRISPR Therapeutics has a...
Via
Benzinga
Intellia Therapeutics Looks To Repeat Its Landmark Success In CRISPR Gene Editing
September 16, 2022
Intellia tested its CRISPR approach in cardiomyopathy and hereditary angioedema.
Via
Investor's Business Daily
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin
September 15, 2022
The market is struggling, yet biotech stocks are acting like it's good times again. Here's why.
Via
Investor's Business Daily
Neurocrine Leads 5 Stocks To Watch In Sickly Market
September 03, 2022
Neurocrine Biosciences leads five medical stocks showing resilience.
Via
Investor's Business Daily
Here's How Much $100 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today
August 31, 2022
CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 16.43% on an annualized basis producing an average annual return of 26.37%. Currently, CRISPR Therapeutics has a...
Via
Benzinga
5 Top Stocks Cathie Wood Is Selling This Week
August 26, 2022
Cathie Wood and her flagship ETF ARKK received $54.2 million of inflows earlier this month. Here's what she's selling.
Via
InvestorPlace
5 Cathie Wood Stocks Signaling “The Bear Market Is Over”
August 22, 2022
These top Cathie Wood stocks are signalling that the bear market is over. For savvy investors, that presents a chance to profit.
Via
InvestorPlace
Why This Analyst Sees A 51% Return On This Cathie Wood-Favored Biotech Stock
August 17, 2022
Biotech stocks have the potential for huge gains if a product or drug is deemed effective and safe, but investing in the shares of those companies can be volatile.
Via
Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth $3,900 Today
August 17, 2022
CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 19.58% on an annualized basis producing an average annual return of 31.2%. Currently, CRISPR Therapeutics has a...
Via
Benzinga
Analysts See Softened Timelines For CRISPR Therapeutics' Sickle Cell Candidate In US
August 09, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2022
August 09, 2022
Via
Benzinga
Karuna Therapeutics To $276? Plus SVB Leerink Almost Doubles Price Target On This Stock
August 09, 2022
Mizuho boosted the price target for Karuna Therapeutics, Inc. (NASDAQ: KRTX) from $190 to $276. Karuna Therapeutics shares fell 1.3% to $238.00 in pre-market trading.
Via
Benzinga
NVIDIA To $240? Here Are 5 Other Price Target Changes For Tuesday
August 09, 2022
Raymond James cut the price target on NVIDIA Corporation (NASDAQ: NVDA) from $250 to $240. Raymond James analyst Melissa Fairbanks maintained the stock with a Strong Buy. NVIDIA shares fell 2.8% to...
Via
Benzinga
Small Cap Biotechs Perk Up On Dealmaking
August 06, 2022
With M&A picking up we would think smaller deals make sense for large cap biopharma to expand pipelines and complement technology.
Via
Talk Markets
Pfizer Is Reportedly In 'Advanced Talks' To Buy Global Blood Therapeutics For $5 Billion
August 05, 2022
Shares of Pfizer's rumored takeover target have rocketed for two days running.
Via
Investor's Business Daily
Cathie Wood Sheds $5M In CRISPR Therapeutics, Scoops Up These Biotech Stocks Instead
August 05, 2022
Cathie Wood-led Ark Investment Management on Thursday sold 70,723 shares of gene editing company CRISPR Therapeutics AG (NASDAQ: CRSP), valued at over $5.58 million, via its flagship fund.
Via
Benzinga
Why Are Gene Editing Stocks NTLA, ALNY, CRSP, BEAM Up Today?
August 03, 2022
Gene editing stocks are a bright spot on the market today after Alnylam announced the success of one of its RNAi therapies, Patisiran.
Via
InvestorPlace
Will a Recession Cause a Housing Crash in 2022?
July 27, 2022
For stock investors looking for real estate exposure, the market dislocation also provides many once-a-decade deals.
Via
InvestorPlace
7 Undervalued Biotech Stocks to Buy Before They Boom
July 25, 2022
Despite recession fears, biological sciences will never go out of style, thus benefitting these undervalued biotech stocks to buy.
Via
InvestorPlace
Small Cap Biotech Stocks Are Trending Well
July 18, 2022
Despite a little weakness last week, small cap biotechs are trending well for traders. For investors entering the trade on July 5 all of our. focus stocks are up except ChemoCentryx.
Via
Talk Markets
< Previous
1
2
...
20
21
22
23
24
25
26
27
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.